NanoViricides, Inc. — Form 10-Q Summary
Reporting period: Fiscal quarter and six months ended December 31, 2013; unaudited. The filing identifies NanoViricides as a development-stage biopharmaceutical company. It had no commercialized products and reported no revenue.
Financial performance and position
| Metric | Quarter ended Dec. 31, 2013 | Six months ended Dec. 31, 2013 | Prior comparable period |
|---|---|---|---|
| Revenue | None reported | None reported | None reported |
| Research and development expense | $1.130 million | $2.305 million | $0.710 million and $1.920 million, respectively |
| General and administrative expense | $0.621 million | $1.335 million | $0.533 million and $0.917 million, respectively |
| Total operating expenses / operating loss | $1.751 million | $3.640 million | $1.244 million and $2.837 million, respectively |
| Net loss | $1.692 million | $7.965 million | $1.208 million and $3.012 million, respectively |
| Operating cash used | Not provided for the quarter | $3.518 million | $2.718 million |
Six-month operating expenses increased about 28% year over year, including higher R&D and G&A. The substantially larger six-month net loss included a $3.826 million loss from the change in fair value of derivatives, compared with $0.227 million in the prior period; this is a non-cash fair-value item. The filing’s six-month 2012 loss-per-share figure appears as positive $0.07 despite the reported net loss, so the text does not provide a clear reliable comparative EPS value. Quarterly basic and diluted loss per share was $0.03.
- Cash and liquidity: Cash and equivalents were $16.949 million at December 31, up from $13.923 million at June 30. Current assets were $17.755 million and current liabilities $1.356 million, implying working capital of about $16.399 million.
- Cash flows and financing: Six-month operating cash use was $3.518 million; investing cash use was $3.358 million, including $2.358 million for property and equipment and $1.000 million of additional security deposit. Financing provided $9.901 million, principally from a September 2013 registered equity-and-warrant offering.
- Debt and liabilities: The balance sheet reported $3.744 million of debentures payable and a $7.578 million derivative liability at December 31. The company had issued $6 million of 8% convertible debentures in February 2013, due January 31, 2017. Total liabilities were $12.678 million.
- Other balance-sheet changes: Net property and equipment increased to $2.721 million from $0.469 million at June 30; security deposits rose to $2.000 million from $1.000 million. Common shares outstanding increased to 50.042 million from 47.026 million, following a 1-for-3.5 reverse split and equity financing.
Material changes and developments
- On September 12, 2013, the company raised $10.309 million gross by selling common-stock units with warrants; reported offering costs were approximately $0.619 million. Certain warrant exercises generated a further $0.186 million in September.
- After the reporting period, a January 2014 registered offering raised $20.030 million gross, before estimated expenses of approximately $1.2 million. It comprised 3.815 million common shares and 2.480 million warrants. Management estimated about $18.8 million net of commissions.
- The common stock began trading on NYSE MKT on September 25, 2013. The company also reported completing governance changes, including independent directors and board committees.
- Research and development remained preclinical. The company reported encouraging preliminary non-GLP safety findings for injectable FluCide (NV-INF-1), including no adverse effects at tested doses, and planned GLP toxicology work needed toward an IND. DengueCide received U.S. and European orphan-drug designations. These are company-reported development findings, not evidence of clinical efficacy or regulatory approval.
Outlook, risks, contingencies, and unusual items
- Management said December cash, together with the $2 million security deposit, supported operations for more than two years at the then-current spending rate; after the January financing it expected funding for Phase I and Phase IIa studies of at least one candidate and advancement of another. These estimates depend on external cost estimates and assumptions the company cautioned may be materially wrong.
- The company expected continuing losses and no near-term revenue. It also said further financing would be required in future periods; its stated potential needs included approximately $10–15 million for certain clinical development and additional funding for facilities, staff, and programs. Clinical timelines, costs, and success are uncertain.
- A planned four-year lease for an 18,000-square-foot laboratory and GMP facility in Shelton had not been finalized. The company had provided $2 million cash collateral for financing associated with the facility and reported approximately $1.1 million used for fixtures and improvements. Inno-Haven is controlled by company President and Chairman Anil Diwan, creating related-party exposure.
- TheraCour, whose majority owner is Dr. Diwan and which is a significant company shareholder, supplies licensed technology and development services. Six-month development costs charged by TheraCour were $1.411 million; the license includes cost-plus charges and a 15% royalty on net sales. No royalties had accrued through December 31, 2013. The filing also reports related-party payables of $0.887 million.
- Two Yidam shareholder matters remained disclosed: a Nevada books-and-records action and a Colorado derivative action. The company denied the claims and reported no litigation accrual; the Nevada Supreme Court had denied the company’s writ petition in September 2013.
- Dr. Krishna Menon resigned as consulting regulatory officer for health reasons; the Chief Scientific Officer assumed interim duties with support from regulatory consultants. The filing’s controls discussion refers to effectiveness assessments as of June 30, 2013, rather than clearly documenting a December 31 assessment.
Important facts for investors to verify
- Reconcile the reported losses and EPS, especially the contradictory six-month 2012 per-share figure, and assess the valuation assumptions behind the large derivative liability and fair-value loss.
- Confirm cash runway against actual burn, planned clinical and facility spending, and the net proceeds and dilution from the January 2014 share-and-warrant offering.
- Review the debenture conversion and interest terms, outstanding warrants, potential share issuance, and the resulting dilution.
- Examine the final facility lease, collateral arrangements, related-party approvals, and the company’s financial and operational dependence on TheraCour.
- Verify clinical-development milestones, required GLP studies and IND plans, and distinguish company-reported preclinical results from independently validated or clinical evidence.
- Check the status of both Yidam cases and clarify the period covered by management’s disclosure-controls assessment.